CLC number:
On-line Access: 2023-03-10
Received: 2022-07-01
Revision Accepted: 2022-12-04
Crosschecked: 2023-03-13
Cited: 0
Clicked: 946
Citations: Bibtex RefMan EndNote GB/T7714
Yi LI, Wenyan SHE, Xiaoran XU, Yixin LIU, Xinyu WANG, Sheng TIAN, Shiyi LI, Miao WANG, Chaochao YU, Pan LIU, Tianhe HUANG, Yongchang WEI. AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2200351 @article{title="AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer", %0 Journal Article TY - JOUR
AAZ2可通过靶向PDK1介导线粒体依赖的凋亡1武汉大学中南医院放化疗科, 湖北省肿瘤医学临床研究中心, 肿瘤生物学行为湖北省重点实验室, 中国武汉, 430071 2武汉大学化学与分子科学学院, 中国武汉, 430071 3武汉大学中南医院中西医结合科, 中国武汉, 430071 概要: 大部分化疗药物可以促进活性氧(ROS)产生,同时ROS可以诱导细胞凋亡。本研究构建了一种有机砷化合物N-(4-(1,3,2-dithiarsinan-2-yl)phenyl)acrylamide(AAZ2),其可通过促进ROS产生诱导胃癌线粒体依赖的细胞凋亡。具体机制为AAZ2通过靶向丙酮酸脱氢酶激酶1(PDK1)导致葡萄糖代谢改变和氧化应激,继而抑制PI3K/AKT/mTOR通路,最终激活半胱天冬酶(caspase)依赖的细胞凋亡。此外,体内实验也证实了AAZ2可以抑制胃癌移植瘤的生长。综上,在胃癌中,AAZ2可以通过靶向PDK1影响葡萄糖代谢及随后的氧化应激反应,抑制PI3K/AKT/mTOR信号通路,最终诱发线粒体依赖的细胞凋亡。 关键词组: Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article
Reference[1]AnwarS, ShamsiA, MohammadT, et al., 2021. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy. Biochim Biophys Acta Rev Cancer, 1876(1):188568. [2]CuiQB, WangJQ, AssarafYG, et al., 2018. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updat, 41:1-25. [3]D'SouzaLC, MishraS, ChakrabortyA, et al., 2020. Oxidative stress and cancer development: are noncoding RNAs the missing links? Antioxid Redox Signal, 33(17):1209-1229. [4]ElliottMA, FordSJ, PrasadE, et al., 2012. Pharmaceutical development of the novel arsenical based cancer therapeutic GSAO for Phase I clinical trial. Int J Pharm, 426(1-2):67-75. [5]FattahiS, Amjadi-MohebF, TabaripourR, et al., 2020. PI3K/AKT/mTOR signaling in gastric cancer: epigenetics and beyond. Life Sci, 262:118513. [6]García-GuerreroE, GötzR, DooseS, et al., 2021. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia, 35:201-214. [7]GuHF, HuangTH, ShenYC, et al., 2018. Reactive oxygen species-mediated tumor microenvironment transformation: the mechanism of radioresistant gastric cancer. Oxid Med Cell Longev, 2018:5801209. [8]HarrisIS, DeNicolaGM, 2020. The complex interplay between antioxidants and ROS in cancer. Trends Cell Biol, 30(6):440-451. [9]HayesJD, Dinkova-KostovaAT, TewKD, 2020. Oxidative stress in cancer. Cancer Cell, 38(2):167-197. [10]JinL, KimEY, ChungTW, et al., 2020. Hemistepsin A suppresses colorectal cancer growth through inhibiting pyruvate dehydrogenase kinase activity. Sci Rep, 10:21940. [11]JoshiSS, BadgwellBD, 2021. Current treatment and recent progress in gastric cancer. CA Cancer J Clin, 71(3):264-279. [12]LinJX, XieXS, WengXF, et al., 2019. UFM1 suppresses invasive activities of gastric cancer cells by attenuating the expression of PDK1 through PI3K/AKT signaling. J Exp Clin Cancer Res, 38:410. [13]MissiroliS, PerroneM, GenoveseI, et al., 2020. Cancer metabolism and mitochondria: finding novel mechanisms to fight tumours. eBioMedicine, 59:102943. [14]NerreterT, LetschertS, GötzR, et al., 2019. Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nat Commun, 10:3137. [15]PaiS, YadavVK, KuoKT, et al., 2021. PDK1 inhibitor BX795 improves cisplatin and radio-efficacy in oral squamous cell carcinoma by downregulating the PDK1/CD47/Akt-mediated glycolysis signaling pathway. Int J Mol Sci, 22(21):11492. [16]PerilloB, di DonatoM, PezoneA, et al., 2020. ROS in cancer therapy: the bright side of the moon. Exp Mol Med, 52(2):192-203. [17]SanzMA, FenauxP, TallmanMS, et al., 2019. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 133(15):1630-1643. [18]Škorja MilićN, DolinarK, MišK, et al., 2021. Suppression of pyruvate dehydrogenase kinase by dichloroacetate in cancer and skeletal muscle cells is isoform specific and partially independent of HIF-1α. Int J Mol Sci, 22(16):8610. [19]SmythEC, NilssonM, GrabschHI, et al., 2020. Gastric cancer. Lancet, 396(10251):635-648. [20]SradhanjaliS, TripathyD, RathS, et al., 2017. Overexpression of pyruvate dehydrogenase kinase 1 in retinoblastoma: a potential therapeutic opportunity for targeting vitreous seeds and hypoxic regions. PLoS ONE, 12(5):e0177744. [21]SchneiderCA, RasbandWS, EliceiriKW, 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods, 9(7):671-675. [22]ShangMT, ZhouZW, KuangWB, et al., 2021. High-precision 3D drift correction with differential phase contrast images. Opt Express, 29(21):34641-34655. [23]TataranniT, PiccoliC, 2019. Dichloroacetate (DCA) and cancer: an overview towards clinical applications. Oxid Med Cell Longev, 2019:8201079. [24]TewariD, PatniP, BishayeeA, et al., 2022. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy. Semin Cancer Biol, 80:1-17. [25]VelpulaKK, BhasinA, AsuthkarS, et al., 2013. Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect. Cancer Res, 73(24):7277-7289. [26]WadgaonkarP, ChenF, 2021. Connections between endoplasmic reticulum stress-associated unfolded protein response, mitochondria, and autophagy in arsenic-induced carcinogenesis. Semin Cancer Biol, 76:258-266. [27]WangP, JinJM, LiangXH, et al., 2022. Helichrysetin inhibits gastric cancer growth by targeting c-Myc/PDHK1 axis-mediated energy metabolism reprogramming. Acta Pharmacol Sin, 43(6):1581-1593. [28]WangQQ, JiangY, NaranmanduraH, 2020. Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases. Metallomics, 12(3):326-336. [29]WangWP, DongXX, LiuY, et al., 2020. Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K/AKT/mTOR, and ROS pathways. Biomed Pharmacother, 131:110661. [30]WengMS, ChangJH, HungWY, et al., 2018. The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance. J Exp Clin Cancer Res, 37:61. [31]WuJ, HendersonC, FeunL, et al., 2010. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs, 28(5):670-676. [32]XuXH, WangHB, LiHY, et al., 2019. S-Dimethylarsino-glutathione (darinaparsin®) targets histone H3.3, leading to TRAIL-induced apoptosis in leukemia cells. Chem Commun, 55(87):13120-13123. Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou
310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE |
Open peer comments: Debate/Discuss/Question/Opinion
<1>